Our Therapeutic Areas

For over 35 years, Gilead has been researching, developing, and distributing innovative medicines in areas with a high need for medical advancements. Our ability to turn scientific knowledge into progress once considered impossible has led to the introduction of over 20 life-changing therapies. Today, we have a strong portfolio and a solid pipeline in the fields of virology and oncology. We will continue to tirelessly pursue innovation in these therapeutic areas to improve care for people with HIV, viral hepatitis, COVID-19, cancer, and beyond.

Improving the HIV Care Landscape

Gilead has helped transform HIV into a treatable, preventable, chronic condition for millions of people. Working closely with the HIV community, we pioneered innovations that were once thought impossible—from the first HIV therapy in just one pill to the first oral therapy for the prevention of HIV infections (PrEP, or pre-exposure prophylaxis).

We are committed to ongoing scientific innovation to provide solutions for the evolving needs of people affected by HIV worldwide.

Driven by our vision to end the HIV epidemic for all people, everywhere, we aim to go beyond science by improving education, expanding access to medications, and removing barriers to care, including stigma and discrimination, through partnerships and collaborations.

Hepatitis C, B, and D Viruses

In the past decade, we’ve helped millions of people with chronic hepatitis C (HCV) achieve a cure. We continue working towards the WHO’s goal of eliminating HCV by 2030. To meet the needs of the most vulnerable and disproportionately affected communities, we collaborate with a wide range of external partners.

Beyond HCV, we also provide treatment options for people with hepatitis B (HBV) and D (HDV). For over 20 years, we’ve been at the forefront of improving HBV treatment. Additionally, we have the first approved therapy for treating chronic hepatitis delta virus (HDV).

Innovating to Treat COVID-19

When COVID-19 emerged and the pandemic began to unfold, we responded quickly by advancing several antiviral compounds that had already shown efficacy against other coronaviruses in lab and preclinical studies. We leveraged decades of experience with antiviral drugs and extensive internal resources to help patients and healthcare professionals reduce the burden of the COVID-19 pandemic. To date, over 13 million people worldwide have benefited from these efforts.

Gilead also voluntarily signed non-exclusive licensing agreements with generic manufacturers to expand access to more than 125 countries, most of which have limited resources.

Advancing Transformative Cancer Research

We have been purposefully building our oncology and hematology-oncology pipeline, aiming to secure more than 20 therapy approvals by 2030 that could transform the treatment of breast cancer, blood cancers, and other cancers. Our goal is to positively impact the lives of more than 500,000 cancer patients worldwide.

Our team at Kite is focused exclusively on cell therapies, which we believe have the potential to revolutionize the treatment of cancer—and possibly other diseases.

In recent years, Gilead and Kite have received eight approvals for oncology indications, including drugs for difficult-to-treat metastatic cancers and cell therapies. At the same time, we have tripled our pipeline, and by the end of 2023, our clinical development program included around 60 active or planned studies.

A Historical Commitment Against Invasive Fungal Infections

For 30 years, Gilead has been investing in the treatment of invasive fungal infections, particularly aspergillosis and candidiasis. We remain dedicated to improving access to antifungal treatments for all individuals who need them.